Use of lincomycin to control respiratory infections in lambs: Effects on health and production

The efficacy of lincomycin to control respiratory infections in lambs was assessed in two trials. In trial I, 72 lambs with active mycoplasmal pneumonia were allocated as follows: lambs in group T2 were treated with lincomycin (5 mg kg−1 bodyweight, intramuscularly) twice 2 days apart, those in group T3 with lincomycin (5 mg kg−1 bodyweight, intramuscularly) thrice with 2-day intervals, those in group O with oxytetracycline (20 mg kg−1 bodyweight, intramuscularly) twice 4 days apart and those in group C were controls. In trial II, 48 25–30-day-old clinically healthy lambs were allocated as follows: lambs in group P2 received two injections of lincomycin (5 mg kg−1 bodyweight, intramuscularly) when 30- and 60-day-old, lambs in group P1/30 received one injection of lincomycin (5 mg kg−1 bodyweight, intramuscularly) when 30-day-old, lambs in group P1/60 received one injection of lincomycin (5 mg kg−1 bodyweight, intramuscularly) when 60-day-old and lambs in group C were controls. In trial I, treatment with lincomycin was associated with improved clinical scores; clinical cure rate 42 days after treatment was 87%, 100%, 87% and 0% for group T2, T3, O and C, respectively (P < 0.001); treated lambs produced 18.5% (T2) or 26.5% (T3) heavier carcass than controls; no lung lesions were seen in group T3 lambs, whilst they were evident in 22% of group T2 or group O lambs and in 72% of control lambs; microorganisms were isolated from lung tissue samples of 5 group C and 1 group O lambs. In trial II, administration of lincomycin was associated with smaller clinical scores; prevalence rate of respiratory disorders at the end of the trial was 17%, 42%, 42% and 58% for group P2, P1/30, P1/60 and C, respectively (P < 0.01); treated lambs were >4.5% heavier than controls; lung lesions were recorded in 1 group P2, 2 group P1/30 and group P1/60 and 5 group C lambs; microorganisms were isolated from 1 group P2, 3 group P1/30, 2 group P1/60 and 5 group C lambs. It is concluded that administration of lincomycin is effective for the treatment and the prevention of mycoplasmal atypical pneumonia in lambs.